Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2026 Earnings Call Transcript May 6, 2026
Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.3.
Najat Khan: Good morning, everyone, and thank you for joining us. Since stepping into this role, I’ve been focused on a singular question: how do we harness the full power of AI to consistently and with urgency create better medicines for patients? That requires bold ambition and a lot of focus...
